• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.32% Nasdaq Down0.01%

    Halozyme Therapeutics, Inc. (HALO)

    -NasdaqGS
    23.34 Up 0.21(0.91%) Jul 31, 4:00PM EDT
    |After Hours : 22.94 Down 0.40 (1.71%) Jul 31, 7:57PM EDT
    Add to Portfolio
    Income StatementGet Income Statement for:
    View: Annual Data | Quarterly DataAll numbers in thousands
    Period EndingDec 31, 2014Dec 31, 2013Dec 31, 2012
    Total Revenue 75,334   54,799   42,325  
    Cost of Revenue22,732  6,246  1,094  
    Gross Profit 52,602   48,553   41,231  
    Operating Expenses
    Research Development79,696  96,640  70,044  
    Selling General and Administrative35,942  32,347  24,812  
    Non Recurring -   -   -  
    Others -   -   -  
    Total Operating Expenses -   -   -  
    Operating Income or Loss (63,036) (80,434) (53,625)
    Income from Continuing Operations
    Total Other Income/Expenses Net242  229  73  
    Earnings Before Interest And Taxes(62,794)(80,205)(53,552)
    Interest Expense5,581  3,274   -  
    Income Before Tax(68,375)(83,479)(53,552)
    Income Tax Expense -   -   -  
    Minority Interest -   -   -  
    Net Income From Continuing Ops(68,375)(83,479)(53,552)
    Non-recurring Events
    Discontinued Operations -   -   -  
    Extraordinary Items -   -   -  
    Effect Of Accounting Changes -   -   -  
    Other Items -   -   -  
    Net Income (68,375) (83,479) (53,552)
    Preferred Stock And Other Adjustments -   -   -  
    Net Income Applicable To Common Shares (68,375) (83,479) (53,552)

    Sign Up for a Free Trial to EDGAR Online Premium!
    Get the critical business and financial information you need for more than 15,000 U.S. public companies.
    Sign Up Now - Learn More

    Currency in USD.